Life Sciences Investors delivered a 40.59% NAV return in 2025, supported by innovation-focused biotechnology. Read the full ...

W hile challenges persist in the short term, there are signs pointing toward long-term growth for life sciences, according to JLL’s 2024 Life Sciences Real Estate Perspective and Cluster Analysis. The ...

The transition from non-life to life was very likely aided by an asteroid hitting Earth, prebiotic chemistry, molecular ...

As the life sciences and Medtech sectors undergo rapid transformation, new priorities are reshaping where companies choose to grow. A new report from the Hickey Institute explores the evolving ...

Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 12:00 PM ESTCompany ParticipantsBrett ...

Quiet for much of last year, particularly amid speculation about the prospects of its mega projects, San Diego-based life science real estate developer IQHQ appears to be taking a different tack in ...

PROVIDENCE – The center of the biotechnology startup cluster Rhode Island leaders hope to grow will be on Richmond Street in Providence's Jewelry District, where the state's first life sciences ...

Research shows that women remain woefully underrepresented at the highest levels of leadership in the life sciences industry. Those who have broken through that glass ceiling, however, are not only ...

It's the final day to submit your nominees for this year's Fiercest Women in Life Sciences! The nomination form will close at 11:59 p.m. ET on Friday, Sept. 26. Every year, we celebrate women making a ...

Novo Nordisk Foundation, the world’s richest philanthropic organisation, is boosting spending beyond its home of Denmark to bolster Europe’s capabilities in fields including quantum computing and life ...

Q4 2025 Management View CEO Paul Richards reported net income of $0.52 per diluted share, stating this was "driven by unrealized gains on our preferred stock and stock warrant investments." He ...

Ed Field is President of BioLabs NC. Mr. Field has 20+ years c-level experience in building and selling numerous early-stage and publicly-traded biotechnology companies. He has been responsible for ...